IHH Healthcare Berhad Valuation

Is IHH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Unter dem Marktwert

  • Deutlich unter dem Marktwert

  • Price-To-Earnings gegen Gleichaltrige

  • Price-To-Earnings gegen Industrie

  • PM vs. Fair Ratio

  • Analysten-Prognose

Share Price vs Fair Value

What is the Fair Price of IHH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Unter dem Marktwert: IHH (MYR6.2) wird unter unserer Schätzung des Fair Value (MYR6.96) gehandelt.

Deutlich unter dem Marktwert: IHH wird um mehr als 20 % unter dem Marktwert gehandelt.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IHH?

Other financial metrics that can be useful for relative valuation.

IHH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA12.2x
PEG Ratio-1.5x

Price to Earnings Ratio vs Peers

How does IHH's PE Ratio compare to its peers?

The above table shows the PE ratio for IHH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45x
KPJ KPJ Healthcare Berhad
29.8x6.3%RM8.3b
FOCUSP Focus Point Holdings Berhad
10.8x11.0%RM328.0m
CENGILD Cengild Medical Berhad
22.5xn/aRM270.7m
APOLLOHOSP Apollo Hospitals Enterprise
116.9x35.9%₹923.1b
IHH IHH Healthcare Berhad
18x-11.6%RM53.5b

Price-To-Earnings gegen Gleichaltrige: IHH ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (22.6x) mit dem Durchschnitt der anderen Unternehmen (44.7x) vergleicht.


Price to Earnings Ratio vs Industry

How does IHH's PE Ratio compare vs other companies in the Asian Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a-9.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a-9.0%
n/an/an/a
No more companies

Price-To-Earnings gegen Industrie: IHH ist aufgrund seines Price-To-Earnings Verhältnisses (22.6x) im Vergleich zum Asian Healthcare Branchendurchschnitt (23.8x) ein guter Wert.


Price to Earnings Ratio vs Fair Ratio

What is IHH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IHH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18x
Fair PE Ratio21.3x

PM vs. Fair Ratio: IHH ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (18.3x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (20.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IHH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM6.04
RM7.13
+18.1%
6.4%RM7.88RM6.40n/a20
Mar ’25RM6.14
RM7.11
+15.8%
6.5%RM7.86RM6.17n/a20
Feb ’25RM6.10
RM7.03
+15.2%
6.3%RM7.70RM6.30n/a18
Jan ’25RM6.03
RM7.00
+16.1%
6.3%RM7.70RM6.30n/a17
Dec ’24RM5.84
RM7.00
+19.9%
6.1%RM7.70RM6.30n/a18
Nov ’24RM5.99
RM7.00
+16.9%
6.2%RM7.70RM6.22n/a18
Oct ’24RM5.85
RM7.02
+20.0%
6.0%RM7.70RM6.22n/a19
Sep ’24RM5.88
RM7.04
+19.7%
5.9%RM7.70RM6.22n/a20
Aug ’24RM5.94
RM7.08
+19.2%
6.0%RM7.70RM6.28n/a21
Jul ’24RM5.89
RM7.06
+19.8%
6.1%RM7.70RM6.28n/a22
Jun ’24RM5.74
RM7.06
+23.1%
5.5%RM7.63RM6.30n/a22
May ’24RM5.73
RM7.09
+23.8%
6.0%RM7.80RM6.30n/a21
Apr ’24RM5.75
RM7.11
+23.6%
5.9%RM7.80RM6.30RM6.0821
Mar ’24RM5.71
RM7.15
+25.2%
6.5%RM7.90RM6.30RM6.1420
Feb ’24RM5.92
RM7.21
+21.8%
6.0%RM7.90RM6.38RM6.1020
Jan ’24RM6.22
RM7.23
+16.3%
6.0%RM7.90RM6.38RM6.0321
Dec ’23RM5.79
RM7.25
+25.2%
5.8%RM7.90RM6.38RM5.8421
Nov ’23RM5.97
RM7.48
+25.3%
6.0%RM8.30RM6.70RM5.9921
Oct ’23RM5.90
RM7.52
+27.4%
5.7%RM8.30RM6.70RM5.8520
Sep ’23RM6.18
RM7.56
+22.3%
5.6%RM8.30RM6.70RM5.8820
Aug ’23RM6.50
RM7.54
+16.0%
7.7%RM8.40RM5.60RM5.9420
Jul ’23RM6.48
RM7.54
+16.4%
7.7%RM8.40RM5.60RM5.8920
Jun ’23RM6.50
RM7.51
+15.6%
8.1%RM8.40RM5.60RM5.7420
May ’23RM6.61
RM7.39
+11.8%
8.3%RM8.33RM5.50RM5.7320
Apr ’23RM6.25
RM7.38
+18.0%
8.4%RM8.33RM5.50RM5.7519

Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.